Melbourne, Australia, 31 March 2016. Adherium Limited (ASX:ADR), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, has appointed a new Senior Vice President of Business Development and has established an operating entity in the UK to serve the European market. Announcement link here.
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-03-31 22:13:502018-01-04 22:14:14ADR Appoints Senior Executive and Establishes Operations in Europe
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-03-23 22:16:212018-01-04 22:16:38Adherium Establishes North American Operations and Appoints Senior Vice President of Business Development to Lead Market Expansion
16 March 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to provide an update on trading since the Company’s Interim Results Statement, released on 8 December 2015. The Directors re-iterate their sales guidance, provided in the Interim Statement, that […]
– Modification of REX to accommodate patients with lower limb loss – Co-operation with Walter Reed National Military Medical Center (WRNMMC), Bethesda, Maryland, US – Potential for “Broad Applicability across the Department of Defense and the Veterans Administration” 11 March 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-03-11 22:15:082018-01-05 19:41:49RXB – Agreement with the United States Army
Effectiveness Submission to the FDA-CVM on Track for 2Q 2016. DUBLIN, Ireland, March 08, 2016 (GLOBE NEWSWIRE) –Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the successful completion of its pilot field study for ranevetmab* (NV-01), the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2016-03-08 22:15:442018-01-05 19:44:33Nexvet Announces Successful Completion of NV-01 Pilot Field Study in Dogs With Osteoarthritis
Link here. RNS Number : 1434H Rex Bionics PLC · 95% Treatment Success and no adverse events · 95% of volunteers said they would like to use REX on a weekly basis · Next new RAPPER II sites will be the Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK; and Austin Health: Royal Talbot Rehabilitation Centre, Melbourne, Australia 27 November […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-11-27 16:41:102018-01-06 16:43:30Rex Bionics Positive Interim Data from RAPPER II
Northridge, CA, USA and Cambridge, United Kingdom, 24 November 2015. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has entered into agreements with specialist wound-care distributors in France and the UK. In France, Medical Z® is a leader in […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-11-24 16:49:062018-01-06 16:51:06Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK
November 23, 2015. Link here. Overview of the symposium: 1, The Animal health industry and opportunities for innovation. 2. An overview of Nexvet: Details of the successful NV-01 pivotal study Next steps for Nexvet’s development programs. PETization and Nexvet’s R&D Finances and corporate structure Partnerships, market opportunities and near-term catalysts Q&A with Nexvet leadership 3. Companion […]
San Diego and Richmond, Va., USA, Ljubljana, Slovenia, and Sydney, Australia, November 19, 2015 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into a Clinical Trial Research Agreement with the University of Adelaide for the purpose of conducting a […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-11-19 16:52:332018-01-06 16:53:10AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections
Primary Endpoint Achieved Conference Call November 16th at 9:00AM ET DUBLIN, Ireland, Nov. 16, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced positive results from its pivotal safety and efficacy study of NV-01, the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2015-11-16 16:53:222018-01-06 16:55:00Nexvet Announces Positive Results From NV-01 Pivotal Study in Dogs With Osteoarthritis
ADR Appoints Senior Executive and Establishes Operations in Europe
/in Portfolio CompaniesMelbourne, Australia, 31 March 2016. Adherium Limited (ASX:ADR), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, has appointed a new Senior Vice President of Business Development and has established an operating entity in the UK to serve the European market. Announcement link here.
Adherium Establishes North American Operations and Appoints Senior Vice President of Business Development to Lead Market Expansion
/in Portfolio CompaniesMelbourne, Australia, March 23, 2016. Link to announcement here.
RXB – Trading Update
/in Portfolio Companies, Rex Bionics16 March 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to provide an update on trading since the Company’s Interim Results Statement, released on 8 December 2015. The Directors re-iterate their sales guidance, provided in the Interim Statement, that […]
RXB – Agreement with the United States Army
/in Portfolio Companies, Rex Bionics– Modification of REX to accommodate patients with lower limb loss – Co-operation with Walter Reed National Military Medical Center (WRNMMC), Bethesda, Maryland, US – Potential for “Broad Applicability across the Department of Defense and the Veterans Administration” 11 March 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology […]
Nexvet Announces Successful Completion of NV-01 Pilot Field Study in Dogs With Osteoarthritis
/in Pharmamark, Portfolio CompaniesEffectiveness Submission to the FDA-CVM on Track for 2Q 2016. DUBLIN, Ireland, March 08, 2016 (GLOBE NEWSWIRE) –Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the successful completion of its pilot field study for ranevetmab* (NV-01), the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of […]
Rex Bionics Positive Interim Data from RAPPER II
/in Portfolio Companies, Rex BionicsLink here. RNS Number : 1434H Rex Bionics PLC · 95% Treatment Success and no adverse events · 95% of volunteers said they would like to use REX on a weekly basis · Next new RAPPER II sites will be the Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK; and Austin Health: Royal Talbot Rehabilitation Centre, Melbourne, Australia 27 November […]
Avita Medical Expands Commercial Reach for ReCell® in Wound Care Market with the Appointment of Distributors in France and the UK
/in Avita Medical, Portfolio CompaniesNorthridge, CA, USA and Cambridge, United Kingdom, 24 November 2015. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has entered into agreements with specialist wound-care distributors in France and the UK. In France, Medical Z® is a leader in […]
Nexvet – Animal Health Symposium
/in Pharmamark, Portfolio CompaniesNovember 23, 2015. Link here. Overview of the symposium: 1, The Animal health industry and opportunities for innovation. 2. An overview of Nexvet: Details of the successful NV-01 pivotal study Next steps for Nexvet’s development programs. PETization and Nexvet’s R&D Finances and corporate structure Partnerships, market opportunities and near-term catalysts Q&A with Nexvet leadership 3. Companion […]
AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections
/in Armata Pharmaceuticals, Portfolio CompaniesSan Diego and Richmond, Va., USA, Ljubljana, Slovenia, and Sydney, Australia, November 19, 2015 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into a Clinical Trial Research Agreement with the University of Adelaide for the purpose of conducting a […]
Nexvet Announces Positive Results From NV-01 Pivotal Study in Dogs With Osteoarthritis
/in Pharmamark, Portfolio CompaniesPrimary Endpoint Achieved Conference Call November 16th at 9:00AM ET DUBLIN, Ireland, Nov. 16, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced positive results from its pivotal safety and efficacy study of NV-01, the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain […]